Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life- AbbVie plans to build out its presence in obesity market
- The most effective method to Pick The Right Speakers
- Putin says Russian forces will seize capital of Zaporizhzhya
- Holyvolt And Wildcat Could Help The West Reclaim Battery Leadership
- Elite Execution Wall televisions for Film Darlings
- Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- Tech Patterns: Contraptions That Will Shape What's in store
- New Cheetos and Doritos will be free of artificial dyes
